Výsledky vyhledávání

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

P424 Do antiTNF through levels correlate with joint extraintestinal manifestations (EIM) activity in Inflammatory bowel disease (IBD) patients?

Publikováno v: Journal of Crohn's and Colitis. 17:i553-i554

Background Inflammatory arthropathies are the most common EIM associated to IBD with a prevalence of 20-50% for axial inflammation and 5-20% for peripheral arthritis. AntiTNF is the preferred treatment in patients with axial spondiloarthritis (AxSp)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6794036a44f4c7c74751683cb5e19fdd
https://doi.org/10.1093/ecco-jcc/jjac190.0554

Zobrazit plný text záznamu

POS0940 FACTORS ASSOCIATED WITH LONG-TERM RETENTION OF TREATMENT WITH GOLIMUMAB IN A LARGE COHORT OF PATIENTS WITH RHEUMATIC DISEASES, WITH UP TO 8 YEARS OF FOLLOW-UP

Autor: M. Pombo-Suarez, D. Seoane-Mato, L. Cea-Calvo, F. Diaz-Gonzalez, F. Sánchez-Alonso, M. Sánchez-Jareño, F. J. Manero Ruiz, L. Ruiz, V. Jovani, I. Castrejon

Publikováno v: Annals of the Rheumatic Diseases. 81:773-774

BackgroundThe long-term retention rate of a biological drug is a surrogate marker of its effectiveness and tolerability.ObjectivesWe assessed the probability of golimumab retention (persistence or drug survival) and the associated factors in a large

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fd57b2a941ccf283e33c8fbe30fe0e1a
https://doi.org/10.1136/annrheumdis-2022-eular.2429

Zobrazit plný text záznamu

AB0907 TREATMENT WITH UPADACINITIB IN REFRACTORY PSORIATIC ARTHRITIS. MULTICENTER STUDY OF FIRST PATIENTS OF CLINICAL PRACTICE

Autor: E. Galíndez-Agirregoikoa, D. Prieto-Peña, B. Joven-Ibáñez, E. Rubio Romero, O. Rusinovich, J. M. Belzunegui Otano, R. Melero, C. Ventín-Rodríguez, V. Jovani, R. Almodovar González, R. Garcia-Vicuna, T. González, I. Calvo, M. L. García-Vivar, S. Perez Barrio, I. Gorostiza, M. A. González-Gay, R. Blanco

Publikováno v: Annals of the Rheumatic Diseases. 81:1583.1-1583

BackgroundUpadacitinib (UPA) is an inhibitor of JAK kinases recently approved by EMA for the treatment of psoriatic arthritis (PsA) in Europe (January 2021) 1. UPA has shown efficacy in refractory patients to anti-TNF 2.ObjectivesA) to assess efficac

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8c5189486997faf4f38f17cf719ff31c
https://doi.org/10.1136/annrheumdis-2022-eular.3263

Zobrazit plný text záznamu

AB0758 Golimumab after discontinuation of non-TNF inhibitors in patients with inflammatory rheumatic diseases: four-year retention rate in the Spanish BIOBADASER registry

Autor: M. Pombo-Suarez, D. Seoane-Mato, F. Diaz-Gonzalez, F. Sánchez-Alonso, L. Cea-Calvo, M. Sánchez-Jareño, V. Jovani, P. Pretel, F. J. Manero Ruiz, I. Castrejon

Publikováno v: Annals of the Rheumatic Diseases. 81:1504.2-1505

BackgroundTreatment options for rheumatic diseases have evolved to include mechanisms of action beyond tumor necrosis factor inhibitors (TNFi). While non-TNFi biologics and targeted synthetic disease-modifying antirheumatic drugs (tsDMARDS) have been

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8b655c9b5e6a21bb8481f0efc54604ae
https://doi.org/10.1136/annrheumdis-2022-eular.1560

Zobrazit plný text záznamu

POS1350 UVEITIS DUE TO IMMUNE-MEDIATED INFLAMMATORY DISEASES TREATED WITH CERTOLIZUMAB PEGOL. MULTICENTER STUDY OF 80 PATIENTS

Publikováno v: Annals of the Rheumatic Diseases. 81:1013.2-1014

BackgroundAdalimumab remains the only biologic approved by the EMA and FDA for the treatment of non-infectious uveitis [1-6]. The reports on efficacy of other anti-TNF drugs such as Certolizumab Pegol (CZP) are scarce.Objectivesto determine the effic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3b04beb95dc0d936b205cfb986e0969c
https://doi.org/10.1136/annrheumdis-2022-eular.3049

Zobrazit plný text záznamu

POS1331 CERTOLIZUMAB PEGOL IN UVEITIS. RETENTION PROBABILITY AND CAUSES OF DISCONTINUATION

Autor: V. Llorenç, M. Sainz-de-la-Maza, Á. García-Aparicio, A. Blanco, C. Hernando-Hernández, J. Cincunegui-Gutiérrez, P. Fanlo, H. Heras, O. García-García, M. Hernández-Garfella, R. Veroz Gonzalez, L. Rodriguez-Melian, V. Jovani

Publikováno v: Annals of the Rheumatic Diseases. 81:1003-1003

BackgroundA personalized disease-specific treatment for non-infectious uveitis (NIU) is challenging. Around 50% of adults with NIU who required classic DMARDs or adalimumab in clinical trials, failed at 6 months during open label phase [1,2]. Therefo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ef9057aa52da90ef010393f811c0e57f
https://doi.org/10.1136/annrheumdis-2022-eular.1211

Zobrazit plný text záznamu

POS1351 CERTOLIZUMAB PEGOL VS ADALIMUMAB IN THE TREATMENT OF REFRACTORY CYSTOID MACULAR EDEMA DUE TO BEHÇET’S DISEASE. MULTICENTER STUDY

Autor: J. L. Martín-Varillas, L. Sanchez-Bilbao, V. Calvo-Río, A. Adan, I. Hernanz Rodriguez, M. Cordero-Coma, D. Díaz Valle, P. Fanlo Mateo, J. De Dios-Jiménez Aberásturi, Á. García-Aparicio, S. Rodríguez Montero, V. Jovani, P. Moya, E. Peña Sainz-Pardo, M. Garijo Bufort, J. L. Hernández, R. Blanco

Publikováno v: Annals of the Rheumatic Diseases. 81:1014-1014

BackgroundCystoid Macular Edema (CME) is the leading cause of blindness in non-infectious uveitis. Behçet’s disease (BD) is one of the diseases most frequently associated with CME [1-4].Objectivesto compare the efficacy and safety of Certolizumab

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e11256bbf38dbe8766a38a2ca19fd7c6
https://doi.org/10.1136/annrheumdis-2022-eular.3331

Zobrazit plný text záznamu

POS0935 HIGHER 5-YEAR SURVIVAL OF CERTOLIZUMAB PEGOL IN YOUNG WOMEN WITH AXIAL SPONDYLOARTHRITIS. BIOBADASER DATA

Autor: M. Moreno, C. Sánchez-Piedra, V. Jovani, R. Cáliz Cáliz, Y. Perez-Vera, V. Emperiale, F. Sanchez-Alonso, M. Pombo, M. Llop Vilaltella, J. Calvet

Publikováno v: Annals of the Rheumatic Diseases. 81:769.1-769

BackgroundCertolizumab pegol (CZP) in women of childbearing age with rheumatoid arthritis has a more favorable response, suggesting a possible distinctive effect in this group1,2.ObjectivesTo evaluate the retention rate of CZP compared to other anti-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fd0b32d852cb190065f8e214e41206b6
https://doi.org/10.1136/annrheumdis-2022-eular.1130

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání